Why Did Monash IVF Group (ASX:MVF) Report Lower FY26 Earnings Despite Cash Flow Improvement?

Aditi Sarkar

02 November 2026 06:10 PM AEDT

Why Did Monash IVF Group (ASX:MVF) Report Lower FY26 Earnings Despite Cash Flow Improvement?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 Revenue declined 0.9% to AUD 269.5 million.
Underlying NPAT was AUD 16.1 million; Operating Cash Flow reached AUD 36.7 million.
Domestic cycle demand, operating costs and Debt remain important monitoring factors.

Monash IVF Group Limited provides fertility and reproductive healthcare services, including assisted reproductive treatment, fertility preservation and related specialist services. Its operations include Australian clinics and international activities. Monash IVF Group (ASX:MVF) shares closed at AUD 0.74 on 2 November 2026. The group’s August 2026 results showed lower annual earnings, while management identified improving domestic Market Share during the second half and progress in international and ancillary services.

FY26 revenue and profitability

Monash IVF Group (ASX:MVF) reported revenue of AUD 269.5 million for the year to 30 June 2026, down 0.9% year on year. Underlying EBITDA declined 19.5% to AUD 53.4 million, and underlying net profit after tax fell 41.2% to AUD 16.1 million. Reported net profit after tax was AUD 8.3 million. The underlying result was below the company’s June guidance range of AUD 17 million to AUD 18 million and included a AUD 1.4 million after-tax prepaid asset write-off.

The results illustrate the different pressures facing revenue and earnings. Deferred price increases in certain east coast markets, labour and supplier costs, and a largely fixed clinical cost base weighed on profitability. Monash IVF Group (ASX:MVF) cited softer domestic stimulated cycle activity, partly offset by growth in international and related services. Those changes affect margins even when total revenue moves only modestly.

Cash flow, borrowing and services

Net operating cash flow rose to AUD 36.7 million in FY26, from AUD 12.9 million in the prior year. Free cash flow improved to AUD 12.9 million, compared with a negative AUD 4.5 million previously. Monash IVF Group (ASX:MVF) incurred Capital Expenditure of AUD 23.8 million and reported net debt of AUD 101.2 million at 30 June 2026. Its debt Facility was increased to AUD 130 million and extended for three years.

The operating cash performance differed from the decline in earnings, demonstrating why both measures deserve attention. Continued cash generation is relevant to funding technology, clinical facilities and debt commitments. The company also indicated that its domestic market share improved over the second half of FY26. This is an operational development, not evidence that volumes or Earnings will necessarily recover at a particular pace.

Clinical and financial risks

Monash IVF Group (ASX:MVF) operates in a sector affected by patient affordability, treatment demand, clinician availability, clinical standards and trust. Changes in stimulated cycle volumes and treatment mix can influence revenue, while staffing and facilities carry costs that may not move proportionately with activity. The company’s Capital Structure adds interest and refinancing considerations.

Monitoring future results requires comparing treatment volumes, domestic market share, international activity, underlying margins and cash conversion. Monash IVF Group (ASX:MVF) has highlighted productivity and cost-base initiatives, but their financial outcomes depend on implementation and service demand.

A recovery in market share is not identical to an increase in absolute treatment volumes: the broader market may still be changing. Management therefore needs to consider both the share of patients served and the overall number of treatments undertaken. Earnings also depend on how much additional activity can be accommodated within existing clinics before significant incremental staffing or facility spending is needed.

Key Insights

The 2026 disclosures show that Monash IVF Group Limited (ASX:MVF) must be evaluated through operating performance, financing and execution together. Its business-specific developments create measurable reporting milestones, while published results describe actual outcomes rather than guaranteed future progress. The next financial updates will clarify how operations and cash requirements evolve.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.